 |
|
|
| |
ACTG A5353: A pilot study of dolutegravir (DTG) + lamivudine (3TC) for initial treatment of HIV-1-infected participants with HIV-1 RNA <500,000 copies/ml
|
| |
| |
Reported by Jules Levin
9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris
1Babafemi O. Taiwo, 2Lu Zheng, 3Amesika N. Nyaku, 2Andrei Stefanescu, 4Paul E. Sax, 5David Haas, 1Baiba Berzins, 6Carole L. Wallis, 7Kimberly Y. Smith, 7Belinda Ha, 8Catherine Godfrey, 9Johnstone Kumwenda, 10Edward Acosta, 11Beverly E. Sha, 12Cornelius Van Dam, 13Roy M. Gulick
1Northwestern University, Chicago, U.S., 2Harvard School of Public Health, Boston, U.S., 3Rutgers, New Jersey Medical School, Newark, U.S., 4Brigham and Women's Hospital, Boston, U.S., 5Vanderbilt University, Nashville, U.S., 6BARC-SA/Lancet Laboratories, Johannesburg, South Africa, 7ViiV Healthcare, Research Triangle Park, U.S., 8NIH, NIAID, Division of AIDS, Rockville, U.S., 9College of Medicine, Johns Hopkins Project, Blantyre, Malawi, 10University of Alabama, Birmingham, U.S., 11Rush University Medical Center, Chicago, U.S., 12Greensboro Clinical Research Site, Greensboro, U.S., 13Weill Cornell Medicine, New York, U.S.
IAS: Dolutegravir-Lamivudine as initial therapy in HIV-1 infected, ARV-naïve patients: 96 week results of the PADDLE trial - (07/25/17)
|
| |
|
|
|
|
|
